caa a22 4500 469026561 CHVBK 20180323132731.0 cr unu---uuuuu 170328e19920801xx s 000 0 eng 10.1007/BF01962545 doi (NATIONALLICENCE)springer-10.1007/BF01962545 Janknegt R. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut Future directions in antimicrobial chemotherapy [Elektronische Daten] [R. Janknegt] New developments in the treatment of bacterial infections are discussed. The most important developments include oral broad-spectrum cephalosporin derivatives and extended-spectrum injectable cephalosporins with improved activity against Gram-positive bacteria. Meropenem is a new carbapenem agent with markedly improved activity against Gram-negative bacteria. Many fluoroquinolones are in various phases of development. The most interesting new compound is sparfloxacin. Azithromycin is a new macrolide which, because of its very long half-life, attains very high levels in most tissues. Potential uses of the newer agents are discussed. Royal Dutch Association for Advancement of Pharmacy, 1992 Azithromycin nationallicence Cefepime nationallicence Cefodizime nationallicence Cefpirome nationallicence Daptomycin nationallicence Meropenem nationallicence Sparfloxacin nationallicence Temafloxacin nationallicence Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 229-244 0031-6911 14:4<229 1992 14 11096 https://doi.org/10.1007/BF01962545 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01962545 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Janknegt R. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 229-244 0031-6911 14:4<229 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer